NeuroSense Therapeutics Ltd.(NRSN)Earnings, Financials & Key Ratios
NRSN•NASDAQ
$0.88
$20M mkt cap·Price updated May 7, 2026
AboutNeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.Show more
- Revenue$0
- EBITDA-$10M+17.9%
- Net Income-$10M-1.0%
- EPS (Diluted)-0.55+33.7%
- ROE-2880.11%-433.6%
- Debt/Equity0.03
- Interest Coverage-31.84-45.3%
NRSN Key Insights
NeuroSense Therapeutics Ltd. (NRSN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 36.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NRSN Price & Volume
NeuroSense Therapeutics Ltd. (NRSN) stock price & volume — 10-year historical chart
Loading chart...
NRSN Growth Metrics
NeuroSense Therapeutics Ltd. (NRSN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2.74%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM28.57%
Return on Capital
10 Years-340.49%
5 Years-381.68%
3 Years-481.63%
Last Year-861.04%
NRSN Peer Comparison
NeuroSense Therapeutics Ltd. (NRSN) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRTA | 566.86M | 10.53 | -2.32 | -92.84% | -260.92% | -49.88% | 0.05 | |
 ACIU | 298.2M | 2.93 | -3.26 | -86.92% | -19.69% | -101.6% | 0.10 | |
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 ANVS | 61.74M | 2.27 | -1.62 | -0.68% | ||||
 IONS | 12.56B | 76.02 | -31.94 | 33.87% | -30.87% | -58.57% | 5.35 | |
 BIIB | 28.25B | 191.38 | 21.67 | 1.39% | 13.92% | 7.55% | 0.38 | |
 CLVT | 1.78B | 2.78 | -9.28 | -3.97% | -5.62% | -2.81% | 0.92 | |
 PTCT | 5.35B | 64.49 | 8.29 | 114.51% | -22.58% |
Compare NRSN vs Peers
NeuroSense Therapeutics Ltd. (NRSN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NRSN Income Statement
NeuroSense Therapeutics Ltd. (NRSN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 3K | 3K | 89K | 97K | 22K | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | -3K▲ 0% | -3K▲ 0.0% | -89K▼ 2866.7% | -97K▼ 9.0% | -22K▲ 77.3% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | 0% | -2866.67% | -8.99% | 77.32% | - |
| Operating Expenses | 1.24M | 2.89M | 5.59M | 13.46M | 12.05M | 9.88M | 8.57M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 337K | 393K | 2.5M | 7.14M | 4.78M | 4.2M | 3.82M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 898K | 2.5M | 3.08M | 6.42M | 7.27M | 5.7M | 4.75M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | -89K | 0 | -22K | 0 |
| Operating Income | -1.24M▲ 0% | -2.89M▼ 133.8% | -5.59M▼ 93.5% | -13.55M▼ 142.6% | -12.05M▲ 11.1% | -9.9M▲ 17.8% | -8.57M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -133.85% | -93.46% | -142.56% | 11.09% | 17.82% | - |
| EBITDA | 0 | -2.88M | -5.58M | -13.46M | -12.03M | -9.88M | -8.55M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | - | -93.55% | -141.1% | 10.66% | 17.86% | 29.84% |
| D&A (Non-Cash Add-back) | 1.24M | 3K | 3K | 89K | 21K | 22K | 18.75K |
| EBIT | -1.22M | -2.83M | -2.89M | -12.32M | -9.66M | -9.9M | -8.57M |
| Net Interest Income | 13K | 61K | -1.15M | 76K | -372K | -309K | -88K |
| Interest Income | 18K | 61K | 0 | 91K | 178K | 2K | 0 |
| Interest Expense | 5K | 0 | 1.15M | 15K | 550K | 311K | 88K |
| Other Income/Expense | 13K | 60K | 1.55M | 1.21M | 1.94M | -308K | -88K |
| Pretax Income | -1.22M▲ 0% | -2.83M▼ 131.4% | -4.04M▼ 42.9% | -12.34M▼ 205.4% | -11.28M▲ 8.6% | -10.21M▲ 9.5% | -8.66M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | -1.14M | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 9.26% | 0% | 0% | 0% |
| Net Income | -1.23M▲ 0% | -2.83M▼ 130.5% | -4.04M▼ 42.9% | -12.34M▼ 205.4% | -10.11M▲ 18.1% | -10.21M▼ 1.0% | -8.66M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -130.48% | -42.89% | -205.37% | 18.1% | -1.02% | -2.74% |
| Net Income (Continuing) | -1.22M | -2.83M | -4.04M | -11.2M | -10.11M | -10.21M | -8.66M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.22▲ 0% | -0.51▼ 131.8% | -0.23▲ 54.9% | -1.07▼ 365.2% | -0.83▲ 22.4% | -0.55▲ 33.7% | -0.34▲ 0% |
| EPS Growth % | - | -131.82% | 54.9% | -365.22% | 22.43% | 33.73% | 28.57% |
| EPS (Basic) | -0.22 | -0.51 | -0.23 | -1.07 | -0.83 | -0.55 | - |
| Diluted Shares Outstanding | 5.45M | 5.52M | 10.86M | 11.51M | 13.64M | 18.6M | 25.4M |
| Basic Shares Outstanding | 5.45M | 5.52M | 10.86M | 11.51M | 13.64M | 18.6M | 25.4M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
NRSN Balance Sheet
NeuroSense Therapeutics Ltd. (NRSN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 913K | 729K | 11.41M | 7.38M | 2.92M | 4.4M | 1.56M |
| Cash & Short-Term Investments | 895K | 699K | 11.06M | 7.09M | 2.64M | 3.38M | 666K |
| Cash Only | 895K | 699K | 11.06M | 3.54M | 2.64M | 3.38M | 666K |
| Short-Term Investments | 0 | 0 | 0 | 3.55M | 0 | 0 | 0 |
| Accounts Receivable | 18K | 30K | 178K | 131K | 166K | 164K | 847K |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | -18 | -67 | -178K | -3.68M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 18 | 67 | 217K | 3.71M | 40K | 35K | 43K |
| Total Non-Current Assets | 42K | 50K | 19K | 329K | 269K | 173K | 128K |
| Property, Plant & Equipment | 7K | 13K | 19K | 306K | 238K | 150K | 105K |
| Fixed Asset Turnover | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 35K | 37K | 0 | 0 | 22K | 23K | 46K |
| Other Non-Current Assets | 0 | 0 | 0 | 23K | 9K | 0 | 46K |
| Total Assets | 955K▲ 0% | 779K▼ 18.4% | 11.43M▲ 1367.4% | 7.71M▼ 32.6% | 3.18M▼ 58.8% | 4.58M▲ 44.0% | 1.68M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | -18.43% | 1367.39% | -32.55% | -58.81% | 44.05% | -29.75% |
| Total Current Liabilities | 37K | 120K | 597K | 1.73M | 3.46M | 1.99M | 2.2M |
| Accounts Payable | 23K | 55K | 39K | 498K | 1.46M | 1.16M | 1.09M |
| Days Payables Outstanding | - | 6.69K | 4.75K | 2.04K | 5.49K | 19.25K | - |
| Short-Term Debt | 0 | 0 | 0 | 64K | 69K | 73K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5K | 29K | 443K | 349K | 545K | 188K | 0 |
| Current Ratio | 24.68x | 6.08x | 19.12x | 4.28x | 0.84x | 2.21x | 2.21x |
| Quick Ratio | 24.68x | 6.08x | 19.41x | 6.41x | 0.84x | 2.21x | 2.21x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 1.83M | 365K | 1.59M | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 147K | 73K | 0 | 19K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 1.83M | 218K | 1.41M | 0 | 0 |
| Total Liabilities | 37K | 120K | 2.42M | 2.09M | 4.94M | 1.99M | 2.2M |
| Total Debt | 0 | 0 | 1.83M | 211K | 142K | 73K | 0 |
| Net Debt | -895K | -699K | -9.23M | -3.33M | -2.5M | -3.31M | -666K |
| Debt / Equity | - | - | 0.20x | 0.04x | - | 0.03x | 0.03x |
| Debt / EBITDA | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | 0.08x |
| Interest Coverage | -247.00x | - | -4.84x | -903.47x | -21.91x | -31.84x | -97.39x |
| Total Equity | 918K▲ 0% | 659K▼ 28.2% | 9.01M▲ 1266.6% | 5.62M▼ 37.6% | -1.87M▼ 133.4% | 2.58M▲ 237.8% | -519K▲ 0% |
| Equity Growth % | - | -28.21% | 1266.62% | -37.61% | -133.35% | 237.83% | -937.82% |
| Book Value per Share | 0.17 | 0.12 | 0.83 | 0.49 | -0.14 | 0.14 | -0.02 |
| Total Shareholders' Equity | 918K | 659K | 9.01M | 5.62M | -1.87M | 2.58M | -519K |
| Common Stock | 1K | 1K | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -1.58M | -4.41M | -8.45M | -20.79M | -26.12M | -36.66M | -41.37M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 24.36M | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NRSN Cash Flow Statement
NeuroSense Therapeutics Ltd. (NRSN) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -582K | -695K | -1.54M | -7.59M | -8.35M | -10.13M | -10.13M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -19.42% | -121.44% | -392.92% | -10.12% | -21.32% | 0% |
| Net Income | -1.22M | -2.83M | -4.04M | -12.34M | -10.11M | -10.21M | -8.66M |
| Depreciation & Amortization | 0 | 3K | 3K | 89K | 21K | 22K | 0 |
| Stock-Based Compensation | 611K | 2.06M | 4.16M | 5.11M | 1.54M | 557K | 557 |
| Deferred Taxes | 0 | 2K | -2.72M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | -2K | 791K | -1.19M | -1.71M | 277K | 5.87K |
| Working Capital Changes | 29K | 71K | 273K | 750K | 1.91M | -781K | 231 |
| Change in Receivables | -3K | -12K | -204K | 55K | 19K | 0 | 71 |
| Change in Inventory | 3K | 0 | 0 | -55K | 0 | 0 | 0 |
| Change in Payables | 23K | 32K | -16K | 459K | 961K | -299K | 0 |
| Cash from Investing | -26K | -9K | -17K | -3.54M | 3.47M | 1K | -7 |
| Capital Expenditures | -7K | -9K | -17K | -70K | -29K | -3K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 3K | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 29K | -6K | 4K | -7 |
| Cash from Financing | 1.42M | 508K | 11.9M | 3.69M | 3.98M | 10.91M | 651 |
| Debt Issued (Net) | 0 | 0 | 1.24M | -79K | -80K | 0 | 0 |
| Equity Issued (Net) | 1000K | 508K | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -3K | 0 | 800K | -96K | 80K | -391K | 651 |
| Net Change in Cash | 809K▲ 0% | -196K▼ 124.2% | 10.36M▲ 5387.8% | -7.52M▼ 172.6% | -903K▲ 88.0% | 738K▲ 181.7% | -1.36K▲ 0% |
| Free Cash Flow | -589K▲ 0% | -704K▼ 19.5% | -1.56M▼ 121.0% | -7.66M▼ 392.0% | -8.38M▼ 9.5% | -10.14M▼ 20.9% | -2K▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -19.52% | -121.02% | -392.03% | -9.5% | -20.94% | - |
| FCF per Share | -0.11 | -0.13 | -0.14 | -0.67 | -0.61 | -0.54 | -0.54 |
| FCF Conversion (FCF/Net Income) | 0.47x | 0.25x | 0.38x | 0.61x | 0.83x | 0.99x | 0.00x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NRSN Key Ratios
NeuroSense Therapeutics Ltd. (NRSN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -358.66% | -83.62% | -168.75% | -539.76% | -2880.11% | 2720.5% |
| Return on Invested Capital (ROIC) | - | - | -987.76% | - | - | 412.35% |
| Debt / Equity | - | 0.20x | 0.04x | - | 0.03x | 0.03x |
| Interest Coverage | - | -4.84x | -903.47x | -21.91x | -31.84x | -97.39x |
| FCF Conversion | 0.25x | 0.38x | 0.61x | 0.83x | 0.99x | 0.00x |
NRSN Frequently Asked Questions
NeuroSense Therapeutics Ltd. (NRSN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
NeuroSense Therapeutics Ltd. (NRSN) grew revenue by 0.0% over the past year. Growth has been modest.
NeuroSense Therapeutics Ltd. (NRSN) reported a net loss of $8.7M for fiscal year 2024.
Dividend & Returns
NeuroSense Therapeutics Ltd. (NRSN) has a return on equity (ROE) of -2880.1%. Negative ROE indicates the company is unprofitable.
NeuroSense Therapeutics Ltd. (NRSN) had negative free cash flow of $0.0M in fiscal year 2024, likely due to heavy capital investments.
Explore More NRSN
NeuroSense Therapeutics Ltd. (NRSN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates